(Q28248687)

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

NMDA receptor subunits: diversity, development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glycine and glycine receptor signaling in hippocampal neurons: diversity, function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Structure-function relationship in serine hydroxymethyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Regulation of serine racemase activity by D-serine and nitric oxide in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glutamatergic regulation of serine racemase via reversal of PIP2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The scaffolding protein PSD-95 interacts with the glycine transporter GLYT1 and impairs its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Functional 'glial' GLYT1 glycine transporters expressed in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glutamate and schizophrenia: beyond the dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Increased cortical kynurenate content in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The G72/G30 gene complex and cognitive abnormalities in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Redox dysregulation, neurodevelopment, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Modulation of [3H]dopamine release by glutathione in mouse striatal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Radical-free biology of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The NMDA antagonist model for schizophrenia: promise and pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Models of schizophrenia in humans and animals based on inhibition of NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Polypharmacy with second-generation antipsychotics: a review of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

New Antipsychotics: Classification, Efficacy, and Adverse Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The effects of L-methionine (without MAOI) in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Long-term outcome of patients who receive ketamine during research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Atypical antipsychotics and the relevance of glutamate and serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A high prevalence of organ-specific autoimmunity in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of D-cycloserine on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Serine racemase binds to PICK1: potential relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

No association between the DRD3 Ser9Gly polymorphism and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

High dose D-serine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A meta-analysis of outcome studies comparing bona fide psychotherapies: Empiricially, "all must have prizes."

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

21 January 2018

Meta-analysis: a review

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586650-000000000-00000

D-serine added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

12 December 2020

Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia

1 reference

12 December 2020

Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital

1 reference

12 December 2020

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

12 December 2020

Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

1 reference

12 December 2020

Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?

1 reference

12 December 2020

Glutamatergic drugs for schizophrenia

1 reference

12 December 2020

D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors.

1 reference

12 December 2020

A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

New pharmacotherapeutic modalities for negative symptoms in psychosis

1 reference

12 December 2020

European multicentre association study of schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms

1 reference

12 December 2020

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

12 December 2020

Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia

1 reference

12 December 2020

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

12 December 2020

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Influence of some psychoactive drugs on mineral metabolism in man

1 reference

12 December 2020

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

1 reference

12 December 2020

Maintenance of neuronal glutathione by glial cells

1 reference

12 December 2020

Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia

1 reference

12 December 2020

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

12 December 2020

Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia

1 reference

12 December 2020

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020